The EMA report that should be released by October 19th should explain in more detail, the reasons for any negative decision. Vivus can then decide if they want to appeal this decision.
According to the EMA's own documents, the reason that the marketing authority for Phentermlne was originally withdrawn in Europe was "due to a lack of therapeutic efficacy", not due to safety concerns.
The lack of therapeutic efficacy was more because the average weight loss for Phentermlne by itself was only about 6.2% (by the way, this is more than Belviq's average of 5.8%), and the EMA requires that the average weight loss is more than 10% of total weight, and at least 5% more than placebo (by the way, Belviq was only 3.3% higher than placebo).
In addition, Phentermlne was only approved for the short-term treatment of obesity (no more than 3 months). Most patients who took Phentermlne for 3 months would regain most, if not all of the weight that they had lost. Obesity is a chronic, long-term condition that needs a long-term treatment like Qsymia (Qsiva).